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ABSTRACT
Background. Unplanned excisions (UE) of soft tissue
sarcomas (STS) carry a high risk for local recurrence (LR)
due to marginal/intralesional resections. However, there
are reports about improved prognosis for UE patients who
have re-resection compared with patients who undergo
planned surgery. The present multicentre study was
designed to define characteristics of UE patients and to
investigate the impact of UE on subsequent therapy and
patient outcomes.
Methods. A total of 728 STS patients (376 males, 352
females; mean age: 58 years) who underwent definite
surgery at one of three tumour centres were retrospectively
included. Time-to-event analyses were calculated with log-
rank and Gray’s tests, excluding patients with primary
metastasis (n = 59). A propensity-score (PS) of being in
the UE group was estimated, based on differences at
baseline between the UE group and non-UE group. An
inverse-probability-of-UE weight (IPUEW) was generated
and time-to-event analyses calculated after IPUEW
weighting.
Results. Before referral, 38.6% of patients (n = 281) had
undergone UE. Unplanned excision patients were younger
(p = 0.036), rather male (p = 0.05), and had smaller
(p\ 0.005), superficially located tumours (p\ 0.005).
Plastic reconstructions (p\ 0.005) and adjuvant radio-
therapy (p = 0.041) more often were needed at re-
resection. In univariable analysis, re-resected patients had
improved overall survival (OS; p = 0.027) and lower risk
of distant metastasis (DM; p = 0.002) than primarily
resected patients, whereas risk of LR was similar
(p = 0.359). After weighting for the IPUEW, however,
differences in terms of OS (p = 0.459) and risk of DM
(p = 0.405) disappeared.
Conclusions. The present study does not support prior
findings of improved outcome for UE patients. Unplanned
excisions have a major impact on subsequent therapy, yet
they do not seem to affect negatively the long-term
oncology outcome.
Diagnosing soft tissue sarcomas among the great num-
ber of benign soft tissue lumps and bumps in routine
practice is challenging. Soft tissue sarcomas are rare,
accounting for only 0.7% of all malignancies estimated to
be diagnosed in 2016 in the United States.1 Also, they often
are asymptomatic or cause unspecific signs and symptoms.
Therefore, STS patients are at risk of delayed or incorrect
diagnosis.2 Because of these issues, unplanned excisions
(UEs) are frequently performed. The proportion of patients
referred following UE ranges between 18 and 53.3% of
patients treated for STS at a sarcoma centre.3–5
Because UEs are usually the result of primary attempts
to remove a lesion that is thought to be benign, they carry a
high risk of residual tumour.4,6 Following UE, decision for
or against re-resection, adjuvant radiotherapy (RTX),
chemotherapy (CTX), or watchful waiting at the specialist
centre is based on surgical and histological reports, resec-
tion margin status, and imaging taken prior to UE.
Considering that marginal or even intralesional resection
margins significantly increase the likelihood for local
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recurrence (LR), re-resections aiming at removal of resid-
ual tumour tissue often are justified.6
The combination of primarily inadequate resection, an
unavoidable delay from UE to definite surgery, and the
peril of residual tumour tissue all suggest that UE patients
would do worse compared with initially adequately treated
patients. Surprisingly, several study groups reported that
UE patients have an identical or even better prognosis than
patients who undergo planned surgery.5–7 It was concluded
that patients with large and high-grade tumours at com-
plicated anatomical sites are far more likely to be referred
directly to a specialist centre, thus causing a selection bias.
According to Lewis et al., however, even adjustment for
these influential factors revealed a prognostic advantage for
re-resected patients.6 The present multicentre study was
designed to elucidate the baseline characteristics of UE
cases, their impact on management at the specialist centre,
and their potential influence on patient outcomes.
METHODS
Patients
We included 728 patients undergoing surgery for STS
between 1998 and 2015 at three sarcoma centres (Depart-
ment of Orthopaedic Surgery, Medical University Graz;
Orthopaedic Hospital Gersthof, Vienna; Sarcoma Centre,
HELIOS-Klinikum Berlin-Buch). The mean patients’ age
was 58 years (range 6–96 years; standard deviation (SD):
±16.9 years); 352 were female (48.4%) and 376 male
(51.6%).
A standard template was used for data collection at each
centre. UEs were defined as unintentionally performed
resections of a subsequently histologically verified STS.
Original tumour size was ascertained from preoperative
MRI and/or medical records or from pathology reports
following primary surgery at the specialist centre or index
surgery performed elsewhere. Tumour grade was recorded
according to the FNCLCC system. Staging was done by
using the AJCC Cancer Staging Manual from 2010.
Patients with metastatic disease (n = 59) or unknown
metastatic status at time of diagnosis (n = 11) were
excluded from time-to-event analyses, resulting in 658
eligible patients.
All patients were discussed in multidisciplinary team
meetings and underwent primary surgery or re-resection
following UE at one of the three sarcoma centres. Need for
plastic, vascular, or endoprosthetic reconstruction at defi-
nite surgery was documented. Neoadjuvant, adjuvant, and
palliative treatments (RTX, CTX) were recorded.
Follow-up was performed until July 2016. Time to last
follow-up or death was calculated from definite surgery to
last known date (most recent clinical appointment, tele-
phone contact, or record in obituary column). The study
was approved by the institutional review boards at the
respective centres.
Statistical Analysis
Statistical analysis was performed using IBM SPSS
statistics version 23.0, Microsoft Excel version 15.19.1 and
Stata (Windows version 13.0, Stata Corp., Houston, TX).
Continuous variables were summarised as means ± SD,
whereas count data were summarised as absolute fre-
quencies with percentages. Associations between two
categorical variables, as tumour grade and UE status, were
analysed with v2 tests (expected cell counts C5) or Fisher’s
exact tests (expected cell counts\5). Means between two
groups were compared with t tests or in case of
heteroscedasticity with Wilcoxon’s rank-sum tests. Median
survival was estimated with the reverse Kaplan–Meier
method by Schemper and Smith. The Kaplan–Meier pro-
duct-limit estimator was used to calculate survivor
functions. Cumulative incidences of LR and distant
metastasis (DM) were estimated with competing risk esti-
mators according to Marubini and Valsecchi, treating
death-from-any-cause as the competing event of interest.
Survivor and cumulative-incidence functions were com-
pared between two or more groups with log-rank and
Gray’s tests, respectively. Uni- and multivariable mod-
elling of time-to-event outcomes was performed with Cox-
proportional hazards models for the overall survival (OS)
endpoint and Fine & Gray’s proportional subdistribution
hazards models for the LR and DM endpoints.
A propensity score (PS), defined as the probability of
undergoing UE, was estimated for each individual patient
according to characteristics at baseline.8 The PS was cal-
culated with a binary logistic regression model, including
the following variables: gender, patient’s age, anatomical
tumour localisation, histologic subtype, tumour depth, size,
and tumour grade. Next, an inverse-probability-of-UE
weight (IPUEW) was constructed, defined as 1/PS for
patients with prior UE and 1/(1-PS) for directly referred
patients. Time-to-event analyses for OS, LR, and DM were
then weighted using this IPUEW. Sensitivity analyses used
a trimmed IPUEW (i.e., the lowest and highest 5% were
removed) that did not materially alter the observed
associations.
RESULTS
Patient characteristics at baseline, tumour-related
parameters, definite treatment, and postoperative informa-
tion are presented in Table 1. The mean tumour size was
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TABLE 1 Descriptive analysis for all patients and differences depending on prior unplanned excision (UE)
Total (n = 728) Unplanned excision Missing p value (v2 test)
No (n = 447) Yes (n = 281)
Centre
A 427 262 165 0 0.484
B 98 65 33
C 203 120 83
Gender
Female 352 229 123 0 0.050
Male 376 218 158
Tumour location
Upper limb 143 73 70 0 \0.005
Lower limb 457 310 147
Trunk 98 50 48
Other 30 14 16
Detailed symptoms
No symptoms 81 54 27 158 0.308
Pain 88 60 28
Increase 303 202 101
Pain ? increase 96 74 22
Tumour size (cm)
0–5 228 83 145 99 \0.005
5–10 181 125 56
[10 220 183 37
Histology
Liposarcoma 183 126 57 0 0.270
Myxofibrosarcoma 161 100 61
Leiomyosarcoma 76 44 32
Synovial Sarcoma 64 34 30
MPNST 21 12 9
Fibrosarcoma 6 3 3
Other 217 128 89
Depth
Superficial 230 93 137 6 \0.005
Deep 492 352 140
Grading
G1 135 88 47 38 0.298
G2 138 79 59
G3 417 267 150
Staging
IA 35 11 24 38 \0.005
IB 98 76 22
IIA 138 50 88
IIB 84 59 25
III 276 198 78
IV 59 40 19
Primary LN metastasis
No 695 430 265 9 0.950
Yes 24 15 9
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8.9 cm (range 0.5–47.0 cm; SD: ±6.3 cm), being signifi-
cantly smaller in superficial STS than in tumours
underneath the fascia (6.1 ± 4.8 cm; 10.2 ± 6.4 cm; t test,
p = 0.005). With 457 cases, most STS were located in the
lower limbs (62.8%), mainly the thigh. A total of 276
patients had AJCC stage III tumours (40%), and a further
TABLE 1 continued
Total (n = 728) Unplanned excision Missing p value (v2 test)
No (n = 447) Yes (n = 281)
Primary distant metastasis
No 680 412 268 5 0.071
Yes 43 32 11
Duration of symptoms (mo)
\6 315 227 88 175 0.008
[6 238 136 92
Amputation
No 663 399 264 0 0.031
Yes 65 48 17
Plastic reconstruction
No 505 345 160 3 \0.005
Yes 220 101 119
Vascular reconstruction
No 687 419 268 3 0.215
Yes 38 27 11
Endoprosthetic devices
No 677 409 268 3 0.022
Yes 48 37 11
R-classification
R0 583 345 238 71 0.001
R1 67 52 15
R2 7 7 0
Postoperative complications
No 561 347 214 3 0.730
Yes 164 99 65
Radiotherapy*
No 284 184 100 10 0.119
Yes 434 256 178
Adjuvant radiotherapy
No 330 216 114 0 0.041
Yes 398 231 167
Chemotherapy*
No 501 292 209 10 0.009
Yes 217 149 68
Local recurrence
No 618 384 234 5 0.431
Yes 105 61 44
Distant metastasis
No 549 324 225 8 0.019
Yes 171 118 53
Statistically significant results are given in bold
* Comprising neoadjuvant, adjuvant, palliative, or combined treatment regimes
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59 had evidence of metastatic disease at time of diagnosis
(8.6%).
The median duration of symptoms before admission was
6 months (range 3 weeks–30 years). In total, 399 patients
had noticed a recent increase of the tumour (70.2%), which
was painless in 303 cases and associated with pain in 96.
An additional 88 patients had experienced pain only
(15.5%), whereas 81 reported no symptoms at all (14.3%).
Altogether, 281 STS patients had undergone UE before
referral (38.6%), with a similar incidence at each centre
(Table 1). The median delay from UE to definite surgery
was 7.9 weeks, with 68.7% of patients treated within
12 weeks (n = 193).
At the centres, most patients underwent wide (n = 492;
67.6%) and compartmental tumour resection (n = 85;
11.7%). Limb-salvage surgery was not feasible in 10.7% of
primary surgeries (n = 48) compared with 6.0% of re-re-
sections (n = 17; p = 0.031).
A total of 220 patients required plastic reconstructions,
as muscular flaps (35.9%) and split-skin grafts (32.3%).
These reconstructions were necessary in 42.7% of re-re-
sections (n = 119) compared with 22.6% of planned
surgeries (n = 101; p\ 0.005). At definite surgery, clear
tumour margins (R-Classification; R0) could be achieved
in 583 cases (88.7%), microscopically intralesional mar-
gins (R1) in 67 cases (10.2%), and macroscopically
intralesional margins (R2) in 7 cases (1.1%).9,10 Postop-
erative complications that necessitated revision developed
in 164 patients (22.6%; Table 1). The rate of postoperative
complications did not significantly differ between UE and
non-UE -patients (23.3 vs. 22.1%; p = 0.730).
Of 434 patients receiving RTX (60.4%), the vast
majority underwent postoperative irradiation of the tumour
bed (n = 398). Patients who underwent re-resection
received adjuvant RTX more often than patients who had
planned surgery (59.4 vs. 51.7%; p = 0.041).
Altogether, 30.2% of patients (n = 217) were adminis-
tered CTX in a neoadjuvant (n = 45), adjuvant (n = 70),
palliative (n = 33), or combined treatment regimen
(n = 69). After a median follow-up of 5.5 years (25th–
75th percentile 3.0–8.4 years), 82 patients were alive with
disease (11.3%) and 399 had no evidence of disease
(54.8%); 129 patients died of STS (17.7%) and 73 died due
to other causes (10%). UE patients accounted for 31%
(n = 40) and non-UE patients for 69.0% (n = 89) of
cancer-related deaths.
Of 658 patients with localised disease at time of diag-
nosis, 92 subsequently developed LR (14.0%), whereas 137
patients (20.8%) developed DM. The 5- and 10-year OS
rates for all patients were 77.7 and 63.8%, respectively. 5
and 10-year risks of LR were estimated at 12.8 and 20.4%
and corresponding risks of DM at 22.3 and 25.0% (Fig. 1).
Tumour size (p = 0.004), grade (p = 0.013), stage
(p\ 0.005), histological subtype (p = 0.007), symptoms
lasting for less than 6 months (p\ 0.005), and use of CTX
(p\ 0.005) were significant predictors of survival using
univariable analysis (Table 2). UE patients undergoing
definite surgery later than 12 weeks had a 113% higher
relative risk for LR (subdistribution hazard ratio (SHR):
2.135; 95% confidence interval (CI) 1.108–4.112;
p = 0.023) and a 186% higher relative risk of DM (SHR:
2.863; 95% CI 1.483–5.537; p = 0.002) than those treated
earlier than 12 weeks.
Univariable analysis revealed that UEs with consecutive
re-resection were significantly associated with improved
OS compared with primary surgeries (hazard ratio (HR):
0.689; 95% CI 0.494–0.961; p = 0.027; Fig. 2a). At 5 and
10 years, 82.3 and 67.5% of patients with underwent
resection were alive compared with 74.8 and 61.4% of
patients after planned surgery. UE patients developed DM
less frequently than patients with planned surgery
(p = 0.002; Fig. 2b), whereas LR-free survival rates were
similar for both groups (p = 0.359; Fig. 2c).
In multivariable analysis, tumour size and grade were
confirmed as independent prognostic factors for OS,
whereas the favourable ‘‘effect’’ of UE did not prevail after
adjustment for selected covariates (HR: 0.737; 95% CI
0.501–1.085; p = 0.122; Table 3).
However, some significant differences at baseline
between patients undergoing UE and those with planned
surgery were observed (Table 1). Tumours undergoing UE
were significantly smaller (p\ 0.005), were preferably
located superficially (p\ 0.005), and more often had been
noticed by patients some time ago (p = 0.008). Male
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FIG. 1 Overall survival (OS) and cumulative incidences of local
recurrence (LR) as well as distant metastasis (DM) calculated for
patients with localised disease at time of diagnosis (n = 658)
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TABLE 2 Univariable Cox-regression analysis regarding overall survival for patients without primary metastasis at time of diagnosis
HR 95% CI p value
Lower Upper
Gender (n = 658)
Female 1 0.794
Male 1.043 0.762 1.427
Tumour location (n = 658)
Upper limb 1
Lower limb 0.788 0.363 1.711 0.547
Trunk 0.774 0.376 1.592 0.486
Other 0.712 0.301 1.683 0.439
Tumour size (cm) (n = 568)
0–5 1
5–10 1.953 1.250 3.051 0.003
[10 1.953 1.276 2.987 0.002
Histology (n = 652)
Fibrosarcoma NE NE NE NE
Liposarcoma 1
Myxofibrosarcoma 2.081 1.225 3.536 0.007
Leiomyosarcoma 3.510 1.966 6.266 \0.005
Synovial sarcoma 2.909 1.548 5.466 0.001
MPNST 3.411 1.522 7.648 0.003
Other 3.212 1.951 5.289 \0.005
Depth (n = 652)
Superficial 1 0.762
Deep 1.055 0.747 1.490
Grading (n = 625)
G1 1
G2 2.526 1.218 5.239 0.013
G3 5.451 2.854 10.411 \0.005
Staging (n = 623)
IA / IB 1
IIA / IIB 2.846 1.434 5.648 0.003
III 6.170 3.214 11.843 \0.005
Unplanned excision (n = 658)
No 1 0.027
Yes 0.689 0.494 0.961
Duration of symptoms (mo) (n = 492)
\6 1 \0.005
[6 0.538 0.369 0.782
Postoperative complications (n = 654)
No 1 0.870
Yes 1.030 0.718 1.478
Radiotherapy* (n = 651)
No 1 0.400
Yes 1.152 0.829 1.600
Adjuvant radiotherapy (n = 657)
No 1 0.495
Yes 1.118 0.812 1.539
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inadvertently compared with females (p = 0.05). UE
patients were younger on average than directly referred
ones (56.5 vs. 59.2 years; p = 0.036). Because most of the
abovementioned parameters are well-established prognos-
tic factors, they potentially have a greater influence on
survival than UE itself.
To adjust for these confounding factors, IPUEW anal-
ysis was performed as described in the ‘‘Methods’’
section. The odds of being in the UE group differed
according to whether tumours were superficially located
(odds ratio (OR) for superficial location to being a non-UE
patient: 0.29, p\ 0.0001). After adjusting for the PS, this
difference vanished (OR: 1.04, p = 0.875), thus supporting
the concept that this PS adequately controlled for imbal-
ances between UE- and non-UE patients. After weighting
for the IPUEW score, UEs with subsequent re-resection
were not significantly associated with an improved survival
any more (HR: 0.85; 95% CI 0.56–1.30; p = 0.459;
Fig. 2d), in conformity with the multivariable analysis.
Differences in terms of DM-free survival were likewise lost
following IPUEW score weighting (p = 0.405; Fig. 2e).
DISCUSSION
In this retrospective, multicentre study, we analysed the
association between unplanned excision, subsequent ther-
apy, local recurrence, distant metastasis, and overall
survival in 728 patients with STS. In univariable analysis,
patients with prior UE had significantly better overall
survival than patients with primary surgery at the tumour
centre. However, favourable prognostic factors, such as
small, low-grade tumours and superficial location, were
more common in patients with UE. These data strongly
support the concept that UEs per se, given that they are
followed by appropriate definite surgery at a tertiary centre,
have no major prognostic impact in patients with STS.
Patients referred following UEs are a widely known
phenomenon, accounting for up to 53.3% of all STS
patients treated at tumour centres.3–5 In our cohort, 38.6%
of patients treated at one of the three centres had undergone
UE outwards. The rates that we found are comparable to
the 37% reported by Lewis et al. and 34.8% observed by
Koulaxouzidis et al.6,11
A combination of various factors tempts physicians to
excise a soft tissue tumour. STS from our cohort under-
going UE had been small and were preferably located
clearly visible in the subcutis. Similar observations have
been made by other investigators.3,6,12 Interestingly, the
quality of symptoms did not significantly alter the rate of
inadvertent resections, albeit patients reporting a long
history of complaints were more likely to undergo UE.
Moreover, we observed a difference for gender and age;
significantly more males and younger patients underwent
UE.
Due to smaller and more often superficially located
tumours, UE patients were less likely to undergo amputa-
tion at definite surgery compared with directly referred
patients. However, in 42.7% of re-resections after UE,
muscular flaps and split-skin grafts were required, whereas
plastic reconstructions became necessary in 22.6% of pri-
mary surgeries only. Similar disparities have been reported
by Potter et al. In their cohort, however, only 5% of
planned surgeries but 30% of re-resections necessitated
plastic-reconstructive soft tissue coverage.13
Because of soft tissue damage, unclear resection mar-
gins or frank residual tumour following UE, radical
therapeutic approaches are chosen during re-resection in
relation to the original tumour size. Whether irradiation
following re-resection reduces rate of LR has been dis-
cussed controversially. Most authors have concluded that
RTX should be administered deliberately, based on tumour
extent, postoperative margin status, and histology.13–15 At
least in high-grade STS [5 cm with a deep location, the
risk for LR seems to be reduced by RTX.14 The small
average-tumour size notwithstanding, significantly more of
our UE patients (59.4%) underwent postoperative irradia-
tion compared with patients who had planned surgery
(51.7%). These findings are consistent with previous
observations.13
Despite more often requiring plastic reconstructions and
receiving adjuvant RTX, UE patients did not develop
postoperative complications more frequently than non-UE
TABLE 2 continued
HR 95% CI p value
Lower Upper
Chemotherapy* (n = 651)
No 1 \0.005
Yes 1.893 1.378 2.601
Statistically significant results are given in bold
NE nonestimable: hazard ratio could not be estimated for the fibrosarcoma-subgroup (n = 6, no deaths during follow-up period)
* Comprising neoadjuvant, adjuvant, palliative, or combined treatment regimes
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Log-rank test p=0.027
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patients in our cohort. There is no doubt, however, that
many UE-patients could be protected from disproportion-
ate treatment strategies in relation to the underlying
pathology if they would be referred directly.
Preoperative RTX has proven effective in the manage-
ment of distinct STS subtypes.16 However, administration
of RTX before definite surgery may not be suitable for UE
patients, due to an elevated risk of perioperative
complications.17
As a result of more complex treatment approaches, UE
are associated with considerable financial consequences.
According to Alamanda et al., professional costs (i.e.,
charges billed by surgeons) significantly increased in re-
resections compared with primary surgeries.18 Even after
adjustment for influential parameters, such as tumour
grade, site, size, and the fitness of patients before surgery,
re-excisions were associated with a 33% increase in pro-
fessional charges.18
Patients subjected to definite surgery at one of the three
tumour centres later than 12 weeks following UE had
a higher risk for LR and DM compared with those
undergoing re-resection shortly after inadvertent resec-
tion. Comparable results have been reported by Funovics
et al. analysing 310 STS patients with a history of prior
UE.19
The OS rate of our patients with localised disease at
time of diagnosis was 77.7% at 5 years and 63.8% at 10
years. In line with literature, large tumour size and high
tumour grade were independent negative prognostic fac-
tors.15 Several studies have reported an elevated risk for
LR despite wide re-resection for prior inadvertently
excised STS compared with patients who underwent
planned surgery, whereas others did not observe any
difference.5,6,13,20,21
We found that patients who underwent UE with con-
secutive re-resection had a significantly better prognosis in
the univariable analysis (p = 0.027). Moreover, they
seemed to have a lower risk of developing DM, whereas
LR-free survival was comparable to patients treated ade-
quately from the beginning.
After adjusting for the IPUEW score, however, the
differences in DM-free survival (p = 0.405) and OS
(p = 0.459) between patients with and without prior UE
disappeared. Fiore et al. reported the same conjuncture in a
cohort of 597 patients with STS, of whom 53.3% had been
referred after UE.5 They used a multivariate analysis,
including tumour size, depth, grade, and histological sub-
type, to estimate the effect of UE on OS.5 In this study, we
also applied multivariable analysis but additionally used
IPUEW score-weighting. Both the multivariable adjust-
ment and the IPUEW score-weighted analysis supported
our conclusions.
A limitation of this study is its retrospective design,
entailing dependency on exhaustive patient history and
detailed medical records during follow-up. Additionally,
our cohort comprises likewise patients with STS of the
TABLE 3 Multivariable Cox-regression analysis concerning overall survival for patients without primary metastasis at time of diagnosis
(n = 543)
HR 95% CI p value
Lower limit Upper limit
Tumour size (cm)
0–5 1
5–10 1.864 1.168 2.975 0.009
[10 2.309 1.438 3.707 0.001
Depth
Superficial 1 0.266
Deep 0.793 0.527 1.193
Grading
G1 1
G2 2.809 1.337 5.902 0.006
G3 5.965 3.066 11.532 \0.005
Unplanned excision
No 1 0.122
Yes 0.737 0.501 1.085
Statistically significant results are given in bold
bFIG. 2 Comparison between patients with prior unplanned excision
(UE) and patients undergoing planned surgery (no UE). Juxtaposition
of results obtained by univariable analysis and IPUEW-weighted
analysis in terms of overall survival (2a vs. 2d), risk of local
recurrence (2c vs. 2f; LR analysis using a 5% trimmed IPUEW), and
risk of distant metastasis (2b vs. 2e)
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extremities, trunk, head, and neck. Moreover, it hardly is
possible to assess the impact of potential overtreatment
following UE on the patient’s prognosis in a retrospective
setting and results apply only to UE patients who have
actually been referred to a tertiary centre. Thus, UE
patients may have a significantly worse prognosis in case
treatment based on the same parameters used for directly
referred patients (e.g., tumour size, depth, grade).
CONCLUSIONS
Our study does not support prior findings that unplanned
excisions improve patient outcomes. There also is no evi-
dence that inadvertent resections might be harmful to
prognosis. Unplanned excisions have, however, an influ-
ence on the extent of subsequent therapeutic procedures.
More radical surgical approaches requiring plastic recon-
struction and the increased need for postoperative
radiotherapy compromise the medical condition of patients
with prior unplanned excisions. For that reason, they must
be avoided by all means.
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